The shortage of chemotherapy treatments persists and is combined with delays by insurers

The shortage of chemotherapy treatments persists and is combined with delays by insurers

While, on the one hand, in Puerto Rico the shortage of drugs, particularly generic ones, for chemotherapy treatments persists, on the other, the lack of quick responses from insurers exacerbates the already difficult process that cancer patients go through in the island, came to light during a public hearing of the Health Committee of the House of Representatives.

The executive director of the Puerto Rico Association of Hematology and Medical Oncology, Jocelyn Serranoindicated in his presentation that, “Although a number of additional initiatives have been taken this year to mitigate drug availability issues compared to previous months, more time is still required for generic drug production to meet existing demand for patients with cancer and other conditions.

Serrano explained that the problem of shortage or lack of availability of medicines –known in English as “drug shortage”–, to treat different diseases, is not new. However, “2023 has been a very challenging year to address this situation,” he stressed, particularly when it has involved critical drugs to treat cancer.

This year, there have been longer periods in which some medicines are not available, while there has been a considerable increase in the number of medicines that are in short supply compared to previous years, Serrano said, referring to the list from the Drug Shortage Database of the Food and Drug Administration (FDA). The effects of the shortage in Puerto Rico and the feelings of oncologists and their patients were collected in a report published by The new day at the end of April.

In response to questions from the representative denis marquez -in the public hearing held last Thursday-, Serrano also pointed out that, in addition to the shortage, the response of insurers who challenge medical criteria when debating the determination of which is the most convenient medication versus the one that the plan continues to be an obstacle. you want to cover for a patient.

“We were seeing that private patient insurers were not responding in the way… with the agility that was expected”, pointed out the executive director, when Marquez asked why the Association had had to go to the Office of the Insurance Commissioner so that patients would not suffer delays in their treatments.

He also highlighted the time it takes insurers to approve a chemotherapy treatment and the fact that they delay the process if a doctor does not expressly put the word “expedited”.

“Is it that someone thinks that a cancer treatment does not have to be expedited? Is there someone in an insurer who thinks that it does not have to be expedited?”, questioned the representative of the Puerto Rican Independence Party (PIP). “In all, in all,” replied Serrano.

Only three of the 11 members attended the public hearing convened by the president of the Commission, representative Sol Higgins Cuadrado. The third legislator present was representative Luis Perez Ortiz. At the hearing, the Health Insurance Administration (ASES) was summoned, which submitted an explanatory memorandum, but did not participate, and the Department of Health, which did not intervene or submit a response to Chamber Resolution 1007, which orders the Health Commission of the Chamber to carry out an exhaustive investigation on the shortage of chemotherapy treatments for cancer patients in Puerto Rico.

The FDA has said that the shortages are caused by factors such as delays and interruptions in production, pharmaceutical closures, delays that companies have experienced in receiving raw materials and components necessary to manufacture the drug, increased demand and even the discontinuation of the drug.

“However, medical organizations are beginning to believe, for the most part, that the shortage of medicines is caused by the low profitability of generic drugs, since mainly the medicines that are in shortage are the generic ones”, Serrano stressed in his presentation.

When interpreting that statement, Marquez asked if he meant that there was intentionally less production of generic treatments because the profit margin is lower, while the production of the brand drug offers a higher margin because it is more expensive.

“Did I understand correctly? That is pure capitalism”, stated the representative. “It could be. That is one of the reasons,” Serrano replied.

The executive director shared that, in Puerto Rico, according to the information collected through the members of the Association, oncologists have faced problems in acquiring generic chemotherapeutic agents, such as Leucovorin, Fluorouracil (5-FU), Capecitabine, Carboplatin, Cisplatin and Sunitinib, among other therapies.

Faced with this reality, at the end of April, the ASES opened the formulary for oncological drugs as a strategy to reduce the possible setbacks that patients would face when accessing brand name drugs and treatments to replace generic ones, which means that an insurer under the Plan Vital cannot deny access to a brand treatment.

Although this does not apply to patients with private insurance, Serrano stated that “in Puerto Rico, sooner or later, cancer patients end up enrolling in the Vital Plan or special coverage due to the high costs of paying for medicines and treatments for this condition, as well as the accessibility offered by the Vital Plan and that is not offered by other medical insurance”.

Currently, the island only has 114 oncologists and hematologists to care for approximately 16,000 patients who are diagnosed with cancer each year, according to data from the Central Cancer Registry of Puerto Rico cited by the Association, plus the thousands of patients who require continuous treatment and still battle to beat the disease.

In her presentation, the Association’s spokesperson stressed that, for the past three years, cancer has been the second leading cause of death in Puerto Rico and the United States. In 2022, 5,253 deaths associated with cancer were reported, 15.2% of the total deaths registered on the island, according to statistics from the Puerto Rico Demographic Registry.

“In order for patients to receive adequate, effective and uninterrupted treatment, it is very important that the market have optimal inventories to meet existing demand, in case of emergency or interruptions in the chain so that patients can acquire medicines in a timely manner. without delay due to lack of accessibility or medical coverage,” Serrano said.

Kumneger Media
Kumneger Media
Kumneger Media is a News and Entertainment Website & Channel. Kumneger Media in addition to News and Entertainment it is the hub of Politics, Movies, Drama, Music, Comedy, Documentary and More!